U.S. Gastro Update eNewsletter
April 2023

Heightened Anxiety and Depression Risk in Individuals With GERD
Patients with gastroesophageal reflux disease (GERD) are more prone to experience comorbid anxiety disorders or depression as a result of a causal relationship, according to findings from a recent publication in Frontiers in Psychiatry. To ascertain this connection, researchers utilized summary statistics from genome-wide association studies. Read more.


Azurity Pharmaceuticals’ Konvomep Now FDA Approved
Azurity Pharmaceuticals recently announced that the FDA approved Konvomep (omeprazole and sodium bicarbonate for oral suspension). Konvomep is approved for the treatment of active benign gastric ulcer and reduction of risk of upper gastrointestinal bleeding in critically ill patients. It is expected that Konvomep will become commercially available in pharmacies nationwide in the first quarter of 2023. Read more.

New Pharmacist Recommendation Series Video
In the latest Pharmacist Recommendation Series video, U.S. Pharmacist Editor-in-Chief Robert Davidson discusses KONVOMEP with Clinical Pharmacist Tammie Lee Demler. In this installment, Dr. Demler explains how Konvomep may give patients, particularly people with difficulty swallowing pills or capsules, an option for treatment tailored to their needs. Click here to view video.

Connect With U.S. Pharmacist
Facebook Twitter USP Google AppUSP Itunes App